Clinical Trial

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Study acronym: TCTN
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To compare disease-free survival (DFS) rate of adjuvant chemotherapy epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly paclitaxel or docetaxel-carboplatin (EC-TCb) in triple-negative breast cancer.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2015-05-21; most recent amendment 2025-07-08.
Status change: Recruiting → Active, Not Recruiting 2025-07-08
Status change: Not Yet Recruiting → Recruiting 2015-12-29
Trial Details
NCT Number NCT02455141
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Breast Neoplasm
Enrollment 786 participants
Start Date 2016-03
Primary Completion 2027-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2025-07-11